Biopharmaceutical Production in Transgenic Animals

A decade of success in expressing a variety of proteins in livestock has brought three human recombinant proteins to human clinical trials. Recent progress has drawn on molecular biology and reproductive physiology to improve the efficiency of producing and reproducing useful transgenic founder animals, and to improve the expression of heterologous proteins.

The market growth has been the driving force on efforts for the development of new therapeutic proteins, in which transgenesis emerges as key component. The use of the transgenic animal platform offers attractive possibilities, residing on the low production costs allied to high productivity and quality of the recombinant proteins

The approval of two mammary gland-derived recombinant proteins for commercial and clinical use has boosted the interest for more efficient, safer and economic ways to generate transgenic founders to meet the increasing demand for biomedical proteins worldwide.

  • Recombinant proteins
  • Cell-based reactors
  • CRISPR

Related Conference of Biopharmaceutical Production in Transgenic Animals

June 08-09, 2026

20th World Drug Delivery Summit

London, UK
July 27-28, 2026

19th World Drug Delivery Summit

Paris, France
July 27-28, 2026

39th World Congress on Pharmacology

Rome, Italy
September 24-25, 2026

6th World Congress on Rare Diseases & Orphan Drugs

Paris, France
November 26-27, 2026

5th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 26-27, 2026

5th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland

Biopharmaceutical Production in Transgenic Animals Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in